DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis – with future targets for further and new patient groups and segments.

DanCann Pharma is a vertically integrated company with upcoming activities from genetic development (research into novel cannabinoids) to the formulation of the pharmaceutical. DanCann Pharma has several tracks, including, but not limited to: imports / distribution, R&D, and own in-house production (cultivation, refining and formulation).

DanCann Pharma is licensed for handling of euphoriant substances, and during the summer 2018, DanCann Pharma was licensed as one of the first companies in Denmark to handle and cultivate cannabis for medical use.